Disease Biomarkers

Three Key Disease Markers¹

The Kidney Health Initiative (KHI) convened a panel of experts to reach a consensus on clinical endpoints in C3G.

Experts concluded that a favourable effect on three particular endpoints would be compelling in supporting evidence of effectiveness for treating C3G.

Proteinuria reduction

An increase in proteinuria is associated with a higher risk of disease progression, while a reduction is linked to a lower risk of progression to kidney failure

eGFR stabilisation

Stabilisation/reduction in rate of decline for eGFR over 6 months is associated with clinical benefit

Histopathology improvement

Reduction in C3 staining is a positive indicator of treatment response

Proteinuria: A Surrogate Endpoint for Kidney Failure^2,3

Short-term changes in proteinuria are strongly associated with risk of kidney failure^1–3

Proteinuria has been proposed as a surrogate endpoint for kidney failure, as it is a major contributor to the progression of several kidney diseases.^1-3

GLOSEN and RaDaR registry data in patients with C3G or primary IC-MPGN:^2,3

C3, complement 3; C3G, C3 glomerulopathy; eGFR, estimated glomerular filtration rate; GLOSEN, Spanish Group for the Study of the Glomerular Diseases; IC-MPGN, immune complex-mediated membranoproliferative glomerulonephritis; KHI, Kidney Health Initiative; RaDaR, The National Registry of Rare Kidney Diseases.

References:

Nester C, et al. Clin J Am Soc Nephrol 2024;19:1201–8.
Caravaca-Fontán F, et al. Nephrol Dial Transplant 2022;37:1270–80.
Masoud S, et al. Kidney Int 2025;108(3):455-469.